Pheochromocytoma and functional paraganglioma

Current Opinion in Oncology

Volumn 17, Issue 1, 2005, Pages 13-18

  Yeo, Heather ^a   Roman, Sanziana ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

CT; MRI; Paraganglioma; Pheochromocytoma; Von Hippel Lindau

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 131; ALPHA 2 ADRENERGIC RECEPTOR; CATECHOLAMINE; CHROMOGRANIN A; CORTICOTROPIN; INTERLEUKIN 6; METADRENALIN; NEURON SPECIFIC ENOLASE; NEUROPEPTIDE Y; NORADRENALIN; NORMETADRENALIN; PARATHYROID HORMONE RELATED PROTEIN; SUCCINATE DEHYDROGENASE; VANILMANDELIC ACID; VASOACTIVE INTESTINAL POLYPEPTIDE;

ADRENALECTOMY; ADRENERGIC SYSTEM; CANCER GENETICS; CANCER RISK; CATECHOLAMINE BLOOD LEVEL; CATECHOLAMINE URINE LEVEL; CHROMAFFIN CELL; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; GENE MUTATION; HORMONE RELEASE; HUMAN; MULTIPLE ENDOCRINE NEOPLASIA; NEUROFIBROMATOSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; ONCOGENE RET; PARAGANGLIOMA; PHEOCHROMOCYTOMA; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN SECRETION; REVIEW; VON HIPPEL LINDAU DISEASE;

3-IODOBENZYLGUANIDINE; ADRENAL GLAND NEOPLASMS; CHROMAFFIN CELLS; DIAGNOSIS, DIFFERENTIAL; HUMANS; MAGNETIC RESONANCE IMAGING; PARAGANGLIOMA; PHEOCHROMOCYTOMA; RADIOPHARMACEUTICALS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 13144249142     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.cco.0000147900.12325.d9     Document Type: Review

References (29)

1. Whalen RK, Althausen AF, Daniels GH: Extra-adrenal pheochromocytoma. J Urol 1992, 147:1.
2. th Eselvier Science, 2004: 1052.
3. Khorram-manesh A, Ahlman H, Oden A, Jansson S: Mortality associated with pheochromocytoma in a large Swedish cohort. ESJO 2004, 556-559. Authors used the National Cancer Registry to identify a cohort of 481 patients with adrenal pheochromocytoma and observed the numbers of death and causes of death in these patients compared to the control population.
4. Sabiston D (ed): Textbook of Surgery, Philadelphia, W.B. Saunders, 2004.
5. Bravo EL, Tarazi RC, Gifford RW Jr, Stewart BH: Circulating and urinary catecholamines in pheochromocytoma. Diagnostic and pathophysiologic implications. N Engl J Med 1979, 301:682-686.
6. Langer SZ, Cavero I, Massingham R: Recent developments in noradrenergic neurotransmission and its relevance to the mechanism of action of certain antihypertensive agents. Hypertension 1980, 2:372-382.
7. Eisenhofer G, Goldstein DS, Walther MM, et al.: Biochemical Diagnosis of pheochromocytoma: how to distinguish true from false positive test results. J of Clin Endocrineol and Metab 2003, 88:1656.
8. Lenders JW, Pacak K, Walther MM: Biochemical diagnosis of pheochromocytoma: which test is best. JAMA 2003, 287:1427-1434.
9. Goldstein DS, Eisenhofer G, Flynn JA, et al.: Diagnosis and localization of pheochromocytoma. Hypertension 2004, 43:907-910.
10. Sawka AM, Jaeschke R, Singh RJ: A comparison of biochemical tests for pheochromocytoma: measurement of fractionated plasma metanepherines compared with the combination of 24-hour urninary metanepherines and catecholamines. J Clin Endocrinol Metab 2003, 88:553-558.
11. Sawka AM, Gafni A, Thabane L, et al.: The economic implications of three biochemical screening algorithms for pheochromocytoma. J Clin Endocrinol Metab 2004, 89:2859-2866. A retrospective review of patients who had been screened for pheochromocytoma and who had measurments of 24-h urinary metanephrines and 24-h urnnary catecholamines. The authors took their data and projected a cost-benefit anaysis using a modeling technique.
12. Shapiro SE, Cote GL: The role of genetics in the surgical management of familial endocrinopathy syndromes. J Am Coll Surg 2003, 197:818-831.
13. Jimenez C, Habra MA, Huang S: Pheochromocytoma and medullary thyroid carcinoma: a new genotype-phenotype correlation of the ret protooncogene 891 germline mutation. J Clin Endocrinol Metab 2004, 89: from MDConsult. Authors report the first case of a family with codon 891 RET mutation to have clinically expressed MTC and pheochromocytoma.
14. Bender BU, Altehofer C, Januszewicz A: Functioning thoracic paraganlioma: association with von Hippel-Lindau Syndrome. J Clin Endocrinol Metab 1995, 80:627.
15. Neumann H, Pawlu C, Peczkowska M: Distinct clinical features of paraganglioma syndromes associated with SDHB and SDHD gene mutations. JAMA 2004, 292:943-951.
16. Ilias I, Pacak K: Current approaches and recommended algorithm for the diagnostic localization of pheochromocytoma. J Clin Endocrinol Metab 2004, 89:479-491.
17. Pacek K, Eisenhofer G, Goldstein DS: Functional imaging of endocrine tumors: role of positron emission tomography. Endocrine Review 2004, 28:568-580.
18. Ilias I, Pacak K: Anatomical and functional imaging of metastatic pheochromocytoma. Ann N Y Acad Sci 2004, 1018:495-504.
19. Ilias I, Yu J, Carrasquillo JA, et al.: Superiority of 6-[18F]-fluorodopamine positron emission tomography versus [131I]- metaiodobenzylguanidine scintigraphy in the localization of metastatic pheochromocytoma. J Clin Endocrinol Metab 2003, 88:4083-4087.
20. Ilias I, et al.: Approaches and recommended algorithm for the diagnostic localization of pheochromocytoma. J Clin Endocrinol Metab 2004, 89:479-491. In this review the current views of the roles of various imaging modalities are discussed with an emphasis on new functional PET imaging agents. The authors suggest an algorithm for diagnostic localization of Pheocrmomocytoma.
21. Kikumori T, Imai T, Kaneko T: Intracval endovascular ultrasonography for large adrenal and retroperitoneal tumors. Surgery 2003, 134:989-993. In this prospective study, patients with suspected IVC invasion underwent intracaval endovascular ultrasonography, the results of which were compared to operative findings.
22. Cherki S, Causeret JC, Lifante J: Traitement actuel des phéochromocytomes: à propos de 50 cas current management of pheochromocytoma. Ann Chir 2003, 128:232-236. This retrospective study evaluates laparoscopic and open adrenalectomy for pheochromocytoma.
23. Rocha MF, Faramarzi-Roques R, Tauzin-Fin P: Laparoscopic surgery for pheochromocytoma. Journal of European Urology 2004, 45:226-232.
24. Zeh HJ, Udelsman R: One hundred laparoscopic adrenalectomies: a single surgeon's experience. Ann Surg Oncol 2003, 10:1012-1017. A single surgeon review of one hundred laparoscopic adrenalectomies done at Johns Hopkins Hospital.
25. Kim A, Quiros R, Mahimer J, et al.: Outcome of laparoscopic adrenalectomy for pheochromocytoma vs aldosteronomas. Arch Surg 2004, 139:526-531. Authors compare the effectiveness of laparoscopic transperitoneal adrenalectomy with that of open adrenalectomy in patients with pheochromocytoma.
26. Iihara M, Suzuki RK: Adrenal-preserving laparoscopic surgery in selected patients with bilateral adrenal tumors. Surgery 2003, 134:1066-1073. The authors reviewed the feasibility and safety of adrenal-preserving laparoscopic surgery in 9 patients with bilateral benign adrenal tumors.
27. Walz M: Extent of adrenalectomy for adrenal neoplasm: cortical sparing (sub-total) versus total adrenalectomy. Surg Clin North Am 2004, 84 From Ovid. A literature review of cortical sparing versus total adrenalectomy.
28. Yip L, Lee J: Surgical management of hereditary pheochromocytoma. J Am Coll of Surg 2003, 20:52-55. The authors performed a retrospective review of the outcomes of all patients who had been diagnosed with hereditary pheochromocytoma.
29. Safford SD, Coleman E, Gockerman J, Moore J: Iodine -131 metaiodobenzylguanidine is an effective treatment for malignant pheochromocytoma and paraganglioma. Surgery 2003, 134:956-962.